Published in Sensors (Basel) on December 03, 2014
Doxorubicin-loaded poly(ethylene glycol)-poly(beta-benzyl-L-aspartate) copolymer micelles: their pharmaceutical characteristics and biological significance. J Control Release (2000) 1.96
Biodistribution and anti-tumor efficacy of doxorubicin loaded glycol-chitosan nanoaggregates by EPR effect. J Control Release (2003) 1.34
The anticancer agent ellipticine on activation by cytochrome P450 forms covalent DNA adducts. Biochem Pharmacol (2001) 1.27
Physical entrapment of adriamycin in AB block copolymer micelles. Pharm Res (1995) 1.24
Polymeric micellar pH-sensitive drug delivery system for doxorubicin. J Control Release (2004) 1.23
Polymer-drug compatibility: a guide to the development of delivery systems for the anticancer agent, ellipticine. J Pharm Sci (2004) 1.22
Multimodal action of antitumor agents on DNA: the ellipticine series. Arch Biochem Biophys (1987) 1.14
Extending nature's leads: the anticancer agent ellipticine. Curr Med Chem Anticancer Agents (2004) 1.11
Magnetic nanoparticles and targeted drug delivering. Pharmacol Res (2010) 1.03
The anticancer drug ellipticine forms covalent DNA adducts, mediated by human cytochromes P450, through metabolism to 13-hydroxyellipticine and ellipticine N2-oxide. Cancer Res (2004) 1.02
Molecular mechanisms of antineoplastic action of an anticancer drug ellipticine. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub (2006) 0.96
Influence of serum protein on polycarbonate-based copolymer micelles as a delivery system for a hydrophobic anti-cancer agent. J Control Release (2005) 0.93
Advances in nano drugs for cancer chemotherapy. Curr Cancer Drug Targets (2011) 0.93
Cytochrome P450- and peroxidase-mediated oxidation of anticancer alkaloid ellipticine dictates its anti-tumor efficiency. Biochim Biophys Acta (2010) 0.92
Diblock copolymer nanoparticles for drug delivery. Crit Rev Ther Drug Carrier Syst (1998) 0.91
Anthracyclines and ellipticines as DNA-damaging anticancer drugs: recent advances. Pharmacol Ther (2011) 0.91
Role of hepatic cytochromes P450 in bioactivation of the anticancer drug ellipticine: studies with the hepatic NADPH:cytochrome P450 reductase null mouse. Toxicol Appl Pharmacol (2007) 0.90
Cytochrome b(5) shifts oxidation of the anticancer drug ellipticine by cytochromes P450 1A1 and 1A2 from its detoxication to activation, thereby modulating its pharmacological efficacy. Biochem Pharmacol (2011) 0.90
Nanotechnologies: a strategy to overcome blood-brain barrier. Curr Drug Metab (2012) 0.90
Self-assembling peptide-based nanoparticles enhance cellular delivery of the hydrophobic anticancer drug ellipticine through caveolae-dependent endocytosis. Nanomedicine (2011) 0.90
DNA adduct formation by the anticancer drug ellipticine in rats determined by 32P postlabeling. Int J Cancer (2003) 0.89
Release of hydrophobic anticancer drug from a newly designed self-assembling peptide. Mol Biosyst (2011) 0.88
The mechanism of cytotoxicity and DNA adduct formation by the anticancer drug ellipticine in human neuroblastoma cells. Biochem Pharmacol (2009) 0.86
DNA adduct formation by the anticancer drug ellipticine in human leukemia HL-60 and CCRF-CEM cells. Cancer Lett (2007) 0.84
Cytotoxicity of and DNA adduct formation by ellipticine in human U87MG glioblastoma cancer cells. Neuro Endocrinol Lett (2009) 0.84
Ellipticines as DNA-targeted chemotherapeutics. Curr Med Chem (2014) 0.83
Cytochrome b5 increases cytochrome P450 3A4-mediated activation of anticancer drug ellipticine to 13-hydroxyellipticine whose covalent binding to DNA is elevated by sulfotransferases and N,O-acetyltransferases. Chem Res Toxicol (2012) 0.83
Thermoresponsive polymers as promising new materials for local radiotherapy. Appl Radiat Isot (2005) 0.82
Formation and persistence of DNA adducts of anticancer drug ellipticine in rats. Toxicology (2007) 0.81
Release of adriamycin from poly(gamma-benzyl-L-glutamate)/poly(ethylene oxide) nanoparticles. Int J Pharm (1999) 0.81
Isolation and partial characterization of the adduct formed by 13-hydroxyellipticine with deoxyguanosine in DNA. Neuro Endocrinol Lett (2008) 0.80
Mammalian peroxidases activate anticancer drug ellipticine to intermediates forming deoxyguanosine adducts in DNA identical to those found in vivo and generated from 12-hydroxyellipticine and 13-hydroxyellipticine. Int J Cancer (2007) 0.80
Modern micro and nanoparticle-based imaging techniques. Sensors (Basel) (2012) 0.79
Role of cytochromes P450 and peroxidases in metabolism of the anticancer drug ellipticine: additional evidence of their contribution to ellipticine activation in rat liver, lung and kidney. Neuro Endocrinol Lett (2010) 0.78
Encapsulation of Ellipticine in poly-(3-hydroxybutyrate-co-3-hydroxyvalerate) based nanoparticles and its in vitro application. Mater Sci Eng C Mater Biol Appl (2012) 0.78
Self-assembling peptide-based nanoparticles enhance anticancer effect of ellipticine in vitro and in vivo. Int J Nanomedicine (2012) 0.78
Preparation of pH-responsive polymer core-shell nanospheres for delivery of hydrophobic antineoplastic drug ellipticine. Macromol Biosci (2013) 0.78
Ellipticine-aimed polymer-conjugated auger electron emitter: multistage organelle targeting approach. Bioconjug Chem (2011) 0.77
Electrochemical study of ellipticine interaction with single and double stranded oligonucleotides. Anticancer Agents Med Chem (2014) 0.77
Molecular binding of self-assembling peptide EAK16-II with anticancer agent EPT and its implication in cancer cell inhibition. J Control Release (2012) 0.77
Synthesis of poly-(3-hydroxybutyrate-co-12 mol % 3-hydroxyvalerate) by Bacillus cereus FB11: its characterization and application as a drug carrier. J Mater Sci Mater Med (2013) 0.76
Multistage-targeted pH-responsive polymer conjugate of Auger electron emitter: optimized design and in vivo activity. Eur J Pharm Sci (2014) 0.76
Pharmacokinetics of peptide mediated delivery of anticancer drug ellipticine. PLoS One (2012) 0.76
Excited state proton transfer dynamics of an eminent anticancer drug, ellipticine, in octyl glucoside micelle. Phys Chem Chem Phys (2014) 0.76
Fine tuning of the pH-dependent drug release rate from polyHPMA-ellipticinium conjugates. Bioorg Med Chem (2013) 0.76
Anticancer agent ellipticine combined with histone deacetylase inhibitors, valproic acid and trichostatin A, is an effective DNA damage strategy in human neuroblastoma. Neuro Endocrinol Lett (2011) 0.76